Snapshot from Apr 21, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Renée Aguiar-Lucander
Person

Renée Aguiar-Lucander

Tracked across 2 events · 14 articles · First seen Feb 11, 2026 · Last active Mar 13, 2026

Sentiment
55
Attention
4
Events
2
Relationships
1
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (2)
4 60
Business
Hansa Biopharma Q4 2025 Earnings and Imlifidase BLA
As CEO of Hansa Biopharma, Renée Aguiar-Lucander provided a positive outlook on the company's performance and strategic direction, highlighting the team's strength and execution focus. Her leadership is seen as instrumental in the company's recent successes, including the BLA filing and pipeline advancements.
Feb 11, 2026 · 7 articles
2 50
Regulatory
FDA Accepts Hansa Biopharma's Imlifidase BLA
Renée Aguiar-Lucander, CEO of Hansa Biopharma, expressed optimism about the United States===Food and Drug Administration's acceptance of the imlifidase BLA, highlighting its importance for the company and patients.
Mar 04, 2026 · 7 articles
Relationships (1)
Hansa Biopharma CEO ↔ Renée Aguiar-Lucander Renée Aguiar-Lucander is the CEO of Hansa Biopharma.
NEWSDESK
Track Renée Aguiar-Lucander live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.